

FILED VIA FACSIMILE
Form PTO-1449

Sheet 1 of 1

Applicant: B. Ron Johnson
Serial No.: 10/816,571
Filing Date: April 1, 2004
For:Docket No.: 15070.6.2
Group: 1614ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESINFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTForeign Patent Documents

Examiner Initial ^a	Document Number	Publ. Date	Country or Patent Office	Sub Class	Class	Trans- lation
/D.J./ 1	EP 0 175 338 A2	03/26/86	EPO	A01N33	12	

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\510000001518V\01.doc

Examiner: /Donna Jagoe/

Date Considered: 11/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



EXPRESS MAIL LABEL NO.: EV 443087844 US

Form 1-100-149

Sheet 1 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANT

U.S. Patent Documents

<u>Examiner Initial*</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Name</u>
/D.J./ 1	6,420,431	07/16/02	Johnson
2	6,414,032	07/02/02	Johnson
3	6,410,599	06/25/02	Johnson
4	6,284,289	09/04/01	Van den Berghe
5	6,211,243	04/03/01	Johnson
6	5,827,870	10/27/98	Chodosh
7	5,767,163	06/16/98	Kundsin
8	5,762,940	06/09/98	Bourbon et al.
9	5,753,270	05/19/98	Beauchamp et al.
10	5,725,875	03/10/98	Noll et al.
11	5,712,257	01/27/98	Carter
/D.J./ 12	5,709,866	01/20/98	Booras et al.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 2 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004.

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

/D.J./	13	5,704,906	01/06/98	Fox
	14	5,678,273	10/21/97	Porcelli
	15	5,661,170	08/26/97	Chodosh
	16	5,637,307	01/10/97	Simmons et al.
	17	5,631,245	05/20/97	Drube
	18	5,527,534	06/18/96	Myhling
	19	5,503,853	04/02/96	Bollen et al.
	20	5,492,932	02/20/96	Kundsin
	21	5,439,685	08/08/95	Augros
	22	5,405,602	04/11/95	Simmons et al.
	23	5,387,611	02/07/95	Rubinstein
	24	5,198,217	03/30/93	Vedros
	25	5,137,724	08/11/92	Balzarini et al.
	26	5,036,095	07/30/91	Andermann
✓	27	5,016,651	05/21/91	Stalcup et al.
/D.J./	28	4,975,217	12/04/90	Brown-Skrobot et al.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 3 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

/D.J./ 29	4,957,734	09/18/90	Miller
30	4,952,204	08/28/90	Korteweg
31	4,929,442	05/29/90	Powell
32	4,895,727	01/23/90	Allen
33	4,887,994	12/19/89	Bedford
34	4,875,602	10/24/89	Chickering et al.
35	4,828,542	05/09/89	Hermann
36	4,822,605	04/18/89	Powell
37	4,797,420	01/10/89	Bryant
38	4,661,354	04/28/87	Finnerty
39	4,507,281	03/26/85	Asculai et al.
40	4,486,450	12/04/450	Bernstein
41	4,394,381	07/19/83	Sherrill
42	4,390,539	06/28/83	Sherrill
43	4,262,007	04/14/81	Sherrill
/D.J./ 44	4,183,684	01/15/80	Avery, Jr.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 4 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

/D.J./	45	4,176,197	11/27/79	Olson
↓	46	3,369,543	02/20/68	Ronco
/D.J./	47	1,822,566	09/08/31	Davies

Foreign Patent Documents

Examiner Initial*	Document Number	Publ. Date	Country or Patent Office	Class	Sub Class	Trans- lation
___ 48	2,143,136	08/23/96	Canada	6		...
___ 49	2 700 698	07/29/94	France	3		Yes
/D.J./ 50	0 478 445	09/24/91	France	3	48no translati	
___ 51	0 190 797	08/13/86	EPO	4		...
___ 52	0 181 184	05/14/86	EPO	4		
___ 53	1 479 480	07/13/77	GB	2		
___ 54	WO 99/08713	02/25/99	PCT	6		...
___ 55	WO 98/11778	03/26/98	PCT	A01N	33/12	Yes
___ 56	WO 98/42188	10/01/98	PCT	A01N	33/12	Yes

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 5 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

Other Documents

(including author (if listed), title, relevant pages, date of publication including at least month and year).

Examiner

Initial*

- _____ 57 *AHFS Drug Information*, pages 3107-3108, 1999.
- _____ 58 *Physicians Desk Reference for Non-Prescription Drugs, Product Information*, pgs. 643, 644, 649, 503, 507, and reference pages to Bactine, and Tanac, 1998.
- _____ 59 Winthrop Laboratories, ZEPHIRAN® CHLORIDE, Informational Brochure, July, 1980.
- _____ 60 *Encyclopedia Britannica, Inc., Definitions of SKIN and SKIN, DISEASES OF*, pgs. 603-609, 1970
- _____ 61 *DentalDots® What are they?*, located at "<http://www.dentaldots.com/whatsadot.htm>," page 1, web page dated July 14, 1999.
- _____ 62 *Viramedx Really Fast Relief for Herpes Related Outbreaks*, located at "<http://www.viramedx.com/>," 1 page, web page dated 6/28/99.
- _____ 63 *Cold Sores Healed in Less than 24 Hours Report Says*, located at "<http://www.viramedx.com/news01.htm>," 2 pages, web page dated 6/28/99.
- _____ 64 *Comparison of Zovirax, Valtrex, Famvir and VirMedx*, located at "<http://www.viramedx.com/compare.htm>," 1 page, web page dated 6/28/99.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- _____ 65 *Herpes Treatment That Works on Genital Herpes Too*, located at "<http://www.viramedx.com/about.htm>," 1 page, web page dated 6/28/99.
- _____ 66 *Herpes Treatment Shows Promise Against Genital Herpes*, located at "<http://viramedx.com/study.htm>," 1 page, web page dated 6/28/99.
- _____ 67 *Results Against Clinical Strains of Herpes Simplex Virus*, located at "<http://www.ciramedx.com/labdata.htm>," 1 page, web page dated 6/28/99.
- _____ 68 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://viramedx.com/clinicaldata.htm>," 1 page, web page dated 6/28/99.
- _____ 69 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://www.ciramedx.com/results.htm>," 5 pages, web page dated 6/28/99.
- _____ 70 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://www.viramedx.com/clinicalsum.htm>," 2 pages, web page dated 6/28/99.
- _____ 71 *Sigma Product Information Sheet, Benzalkonium Chloride*, located at "<http://www.sigma-sial.com/sigma/proddata/b1383.htm>.
- _____ 72 *ViraMedix, Antiviral Activity of Viracea® Against Acyclovir Resistant Strains of Herpes Simplex Virus (HSV)*, located at "<http://www.herpesccontrol.com/acyresist.htm>," by K.D. Thompson et al., The University of Chicago and Meryx Pharmaceutical, Chicago, IL (study results found at <http://www.herpesccontrol.com/figure3.htm>), © 1998.
- _____ 73 *ViraMedix News Release, Announcing the First OTC Treatment Proven to "Kill" the Herpes Virus that Causes Cold Sores, Fever Blisters and Related Outbreaks, Healing the Outbreak in Usually Less Than 24 Hours/Timely Introduction in Light of Recent News of the Spread of Herpes Caused Outbreaks and Just in Time*
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 7 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

for the Summer Sun Caused Outbreaks of Cold Sores, located at <http://www.herpesccontrol.com/news01.htm>, © 1998.

____ 74 Study Results, *Testimonials*, located at <http://www.herpesccontrol.com/results.htm>, © 1998.

____ 75 Berti, et al., *Transcutaneous Drug Delivery: A Practical Review*, Mayo Clin. Proc., Vol. 70, pages 581-586, June 1995.

____ 76 Choi, et al., *The Pretreatment Effect of Chemical Skin Penetration Enhancers in Transdermal Drug Delivery Using Iontophoresis*, Skin Pharmacol. Appl. Skin Physiol., pages 326-335, 1999.

____ 77 Comfort et al., *Enhanced Transport in a Therapeutic Transdermal System*, Biomaterials, Vol. 11, No. 9, pages 729-733, November 1990.

____ 78 Fang et al., *Development and Evaluation on Transdermal Delivery of Enoxacin Via Chemical Enhancers and Physical Iontophoresis*, Journal of Controlled Release, Vol. 54, pages 293-304, 1998.

____ 79 Fang et al., *Evaluation of Transdermal Iontophoresis of Enoxacin From Polymer Formulations: In Vitro Skin Permeation and In Vivo Microdialysis Using Wistar Rat as an Animal Model*, International Journal of Pharmaceutics 180, pages 137-149, 1999.

____ 80 Gismondo, et al., *Efficacia Antimicrobica e Sporicida di Varie Soluzioni Disinfettanti*, Minerva Medica, (Italy) Vol. 86, pages 21-32, January-February 1995 (English translation attached: *Antimicrobial and Sporicidal Efficacy of Some Disinfectant Solutions*).

____ 81 James Alexander Corporation flyer, *Medicaine® Sting and Bite Relief Formula Flyer*, 1997.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 8 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- _____ 82 James Alexander Corporation flyer, *Medicaine® Topical Antiseptic*, 1997.
- _____ 83 James Alexander Corporation flyer, *Unit Dose Swabs*, 1997.
- _____ 84 Jin et al., *Effect of Application Volume of Ethanol-Isopropyl Myristate Mixed Solvent System on Permeation of Zidovudine and Probenecid Through Rat Skin*, Drug Development and Industrial Pharmacy, Vol. 26 No. 2, pages 193-198, 2000.
- _____ 85 Johnson, et al., *Supergistic Effects of Chemical Enhancers and Therapeutic Ultrasound on Transdermal Drug Delivery*, Journal of Pharmaceutical Sciences, Vol. 85, No. 7, pages 670-679, July 1996.
- _____ 86 Kanikkannan, et al., *Structure-Activity Relationship of Chemical Penetration Enhancers in Transdermal Drug Delivery*, *Current Medicinal Chemistry*, Vol. 7, No. 6, pages 593-608, 2000.
- _____ 87 Martindale, The Extra Pharmacopoeia, *Benzethonium Chloride/Benzyl Alcohol*, page 1119, Royal Pharmaceutical Society, 1996.
- _____ 88 Martindale, The Extra Pharmacopoeia, *Disinfectants and Preservatives*, pages 1114-1116, Royal Pharmaceutical Society, 1996.
- _____ 89 Martindale, The Extra Pharmacopoeia, *Ethyl Hydroxybenzoate/Magenta*, page 1137, Royal Pharmaceutical Society, 1996.
- _____ 90 Martindale, The Extra Pharmacopoeia, *Local Anesthetics*, pages 1317, 1320-1321, Royal Pharmaceutical Society, 1996.
- _____ 91 The Merck Index, An Encyclopedia of Chemicals, drugs, and Biologicals, Twelfth Edition, pages 177 and 180, 1996.
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 9 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- ____ 92 Meyler's Side Effects of Drugs, An Encyclopedia of Adverse Reactions and Interactions, *Antiseptic Drugs and Disinfectants*, Chapter 24, pages 643-644 and 664-665, 1996.
- ____ 93 Sanofi Pharmaceuticals, Inc., *Zephiran® Chloride*, Brand of Benzalkonium Chloride, 1997.
- ____ 94 Williams, et al., *Skin Absorption Enhancers*, Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4), pages 305-355, 1992.
- ____ 95 Wu et al., *In Vitro Effect of Penetration Enhancers on Sodium Nonivamide Acetate in Rat Skin*, Biol. Pharm. Bull., Vol. 18, No. 12, pages 1790-1792, 1995.

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL LABEL NO.: EV 443087844 US

Form PTO-1449

Sheet 10 of 10

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\MLA0000001922V001.doc

Examiner: /Donna Jagoe/

Date Considered: 11/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 1 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESSUPPLEMENTAL INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTU.S. Patent Documents

<u>Examiner Initial*</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Name</u>	<u>Class</u>	<u>Sub Class</u>	<u>Filing Date</u>
/D.J./						
1	4,420,484	12/13/83	Gorman et al.	424	326	11/12/81
2	4,464,398	08/07/84	Sheets et al.	424	329	08/11/81
3	4,523,589	06/18/85	Krauser	128	203.27	12/22/83
4	4,532,128	07/30/85	Sheldon et al.	424	78	09/17/84
5	4,599,335	07/08/86	Rentzea et al.	514	255	07/31/85
6	4,745,132	05/17/88	Swered et al.	514	634	07/31/86
7	4,778,813	10/18/88	Fenyess et al.	514	357	01/30/85
8	4,820,737	04/11/89	Schoenwald et al.	514	654	03/16/88
9	4,870,108	09/26/89	Page	514	642	09/20/88
10	4,898,888	02/06/90	Baldone	514	642	07/05/88
11	4,902,720	02/20/90	Baldone	514	642	07/05/88
12	4,914,132	04/03/90	Donofrio et al.	514	643	05/25/89
13	4,923,899	05/08/90	Wachman et al.	514	642	06/23/88
14	4,983,635	01/08/91	Martin	514	643	09/12/88
/D.J./						
15	4,994,199	02/19/91	Scardera et al.	252	106	04/16/90

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 2 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

<u>10.J./</u>	16	5,026,561	06/25/91	Bourbon et al.	424	673	09/20/88
	17	5,030,659	07/09/91	Bansemir et al.	514	635	02/08/90
	18	5,039,688	08/13/91	Lewis	514	358	04/14/89
	19	5,124,359	06/23/92	Wachman et al.	514	642	08/27/91
	20	5,158,766	10/27/92	Greenwald et al.	424	78.33	06/28/90
	21	5,284,875	02/08/94	Martin	514	643	04/16/93
	22	5,320,805	06/14/94	Kramer et al.	422	28	05/15/91
	23	5,338,748	08/16/94	Wachman et al.	514	358	12/09/93
	24	5,344,838	09/06/94	Wachman et al.	514	358	12/08/93
	25	5,446,014	08/29/95	Schuppiser et al.	504	250	07/26/91
	26	5,514,640	05/07/96	Jones et al.	504	158	09/19/94
	27	5,516,758	05/14/96	Stevens et al.	514	12	12/23/93
	28	5,531,984	07/02/96	Staats	424	78.07	08/08/94
	29	5,753,711	05/19/98	Schwabe et al.	514	643	03/18/97
	30	5,897,872	04/27/99	Picciano	424	434	11/12/97
	31	5,922,693	07/13/99	Oldenhove	514	63	02/20/98
	32	5,939,461	08/17/99	Siqueira	514	642	08/15/95
<u>✓</u>	33	5,962,391	10/05/99	Oldenhove	510	369	08/04/97
<u>10.J./</u>	34	5,968,986	10/19/99	Dyer	514	643	01/14/98

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 3 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

<u>/D.J./</u>	35	5,994,383	11/30/99	Dyer et al.	514	390	11/18/97
<u>—</u>	36	5,997,893	12/07/99	Jampani et al.	424	405	01/20/98
<u>—</u>	37	6,013,677	01/11/00	Dyer	514	643	01/06/99
<u>—</u>	38	6,087,400	07/11/00	Dyer et al.	514	643	06/11/99
<u>—</u>	39	6,165,494	12/26/00	Picciano	424	434	04/07/00
<u>—</u>	40	6,171,611	01/09/01	Picciano	424	434	01/19/99
<u>—</u>	41	6,187,332	02/13/01	Gern et al.	424	434	06/14/99
<u>—</u>	42	6,248,343	06/19/01	Jampani et al.	424	405	12/13/99
<u>—</u>	43	6,329,353	12/11/01	Dalrymple et al.	514	77	11/11/99
<u>—</u>	44	6,342,537	01/29/02	Thomsen et al.	514	724	10/13/99
<u>—</u>	45	6,344,210	02/05/02	Fust	424	435	02/16/01
<u>—</u>	46	6,348,503	02/19/02	Squires	514	642	02/12/96
<u>—</u>	47	6,350,784	02/26/02	Squires	514	642	03/26/97
<u>—</u>	48	6,355,684	03/12/02	Squires	514	643	05/08/96
<u>—</u>	49	6,419,850	07/16/02	Rouleau	252	180	01/10/97
<u>—</u>	50	6,436,885	08/20/02	Biedermann et al.	510	131	12/15/00
<u>—</u>	51	6,441,045	08/27/02	Birnbaum	514	643	11/03/99
<u>✓</u>	52	6,444,707	09/03/02	Lampe et al.	514	642	08/22/00
<u>/D.J./</u>	53	6,525,034	02/25/03	Dalrymple et al.	514	77	10/19/01

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 4 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

<u>10/11</u>	54	2001/0007651	07/12/01	Fust	424	49	02/16/01
	55	2002/0006961	01/17/02	Katz et al.	514	625	05/01/01
	56	2002/0136768	09/26/02	Staats	424	484	11/13/01
	57	2002/0151521	10/17/02	Burke et al.	514	54	07/11/01
	58	2002/0161046	10/31/02	Konowalchuk et al.	514	557	12/06/01
	59	2002/0165277	11/07/02	Konowalchuk et al.	514	557	02/28/01
	60	2002/0165278	11/07/02	Konowalchuk et al.	514	557	12/06/01
	61	2002/0188028	12/12/02	Johnson	514	643	07/22/02
<u>10/11</u>	62	2002/0197212	12/26/02	Osbakken et al.	424	45	07/09/02
<u>10/11</u>	63	2003/0013769	01/16/03	Mukkamala et al.	514	642	05/06/02

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 5 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\SJP0000001742V001.doc

Examiner: /Donna Jagoe/

Date Considered: 11/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESSUPPLEMENTAL INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTForeign Patent Documents

<u>Examiner</u> <u>Initial*</u>	<u>Document</u> <u>Number</u>	<u>Publ.</u> <u>Date</u>	<u>Country or</u> <u>Patent Office</u>	<u>Sub</u> <u>Class</u>	<u>Class</u>	<u>Trans-</u> <u>lation</u>
/D.J./ 1	EP 0872248 A2	10/21/98	EPO	A61K	47/48	

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\JP0000004710V001.doc

Examiner:

/Donna Jagoe/

Date Considered:

11/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESSUPPLEMENTAL INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTU.S. Patent Documents

<u>Examiner Initial*</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Name</u>	<u>Class</u>	<u>Sub Class</u>	<u>Filing Date</u>
/D.J./ 1	5,906,814	05/25/99	Epstein	424	78.02	10/22/96

Foreign Patent Documents

<u>Examiner Initial*</u>	<u>Document Number</u>	<u>Publ. Date</u>	<u>Country or Patent Office</u>	<u>Sub Class</u>	<u>Class</u>	<u>Trans- lation</u>
/D.J./ 2	WO 97/29742	08/21/97	EPO	A61K	31/045	

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED ELECTRONICALLY

Form PTO-1449

Sheet 2 of 2

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\SJP0000002382V001.doc

Examiner:

/Donna Jagoe/

Date Considered:

11/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
